Granules India Expands into Peptide Segment with Acquisition of Swiss Firm
Granules India is set to enter the peptide segment and Contract Development and Manufacturing Organisation (CDMO) business through the acquisition of Swiss firm Senn Chemicals AG for ₹192.5 crore (CHF 20 million).
Acquisition Details
Founded in 1963 and headquartered in Dielsdorf, Switzerland, Senn Chemicals AG specializes in custom peptide manufacturing, serving global clients in pharmaceuticals, cosmetics, and theragnostics. The acquisition, subject to certain conditions, is expected to close in the first half of 2025.
Strategic Rationale
The acquisition brings Senn's expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationships. This will enable Granules to enter the high-growth peptide-based therapeutics market, including the rapidly expanding peptide-based anti-diabetic and anti-obesity sector, focusing on Glucagon-like peptide-1 (GLP-1) receptor agonists and other next-generation therapeutics.
GLP-1 Based APIs
Granules and Senn are jointly developing two GLP-1 based active pharmaceutical ingredients (APIs), with plans to expand the portfolio using Senn’s R&D capabilities.
Expansion of CDMO Capabilities
With this acquisition, Granules will leverage Senn’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion. This aims to meet the growing demand for Amino Acid Derivatives (AAD), peptide fragments, and peptide-based therapeutics.
CMD's Perspective
Granules CMD Krishna Prasad Chigurupati stated that the acquisition marks a significant milestone, allowing the company to enter the rapidly growing peptide therapeutics segment and acquire CDMO capabilities. He emphasized that Senn’s expertise in peptide synthesis, combined with Granules' large-scale, cost-efficient manufacturing capabilities, will position them to deliver high-quality peptide-based solutions globally.
Disclaimer: The views and investment tips expressed in this article are for informational purposes only and do not represent financial advice. The views expressed are those of the sources cited and not necessarily those of this website or its management. Investing in equities or other financial instruments carries the risk of financial loss. Readers must exercise due caution and conduct their own research before making any investment decisions. We are not liable for any losses incurred as a result of decisions made based on this article. Please consult a qualified financial advisor before making any investment.
0 comments:
Post a Comment